

Name: DEMO ULTRA

Date: 01-23-2026

Name	Results
Hereditary hemochromatosis type 1 (HFE gene)	Variant present
ARSACS (Autosomal recessive spastic ataxia of Charlevoix-Saguenay)	Variant absent
Achromatopsia	Variant absent
Acute intermittent porphyria (HMBS gene)	Variant absent
Agenesis of the Corpus Callosum with Peripheral Neuropathy (ACCPN)	Variant absent
Alpha-1 Antitrypsin Deficiency	Variant absent
Alpha-mannosidosis	Variant absent
Amyloidosis, Finnish-type (GSN gene)	Variant absent
Autosomal Dominant Limb-Girdle Muscular Dystrophy	Variant absent
Autosomal Dominant Multiple Epiphyseal Dysplasia	Variant absent
Autosomal Dominant Polycystic Kidney Disease	Variant absent
Autosomal Dominant Retinitis Pigmentosa	Variant absent
Autosomal recessive limb-girdle muscular dystrophy	Variant absent
Autosomal recessive polycystic kidney disease	Variant absent
Autosomal recessive retinitis pigmentosa	Variant absent
Beta Thalassemia	Variant absent
Biotinidase deficiency	Variant absent
Birt-Hogg-Dube syndrome	Variant absent
Bloom syndrome	Variant absent
Brugada Syndrome	Variant absent
Canavan Disease	Variant absent
Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2 gene)	Variant absent
Catecholaminergic Polymorphic Ventricular Tachycardia (RYR2 gene)	Variant absent
Catecholaminergic Polymorphic Ventricular Tachycardia (TRDN gene)	Variant absent
Cerebrotendinous Xanthomatosis	Variant absent
Classical homocystinuria due to CBS deficiency	Variant absent
Congenital Myasthenic Syndrome (CHRNBT1 gene)	Variant absent
Congenital Stationary Night Blindness (Oguchi Disease)	Variant absent
Congenital disorder of glycosylation type 1a (PMM2-CDG)	Variant absent
Congenital disorder of glycosylation type 1c (ALG6 gene)	Variant absent
Congenital disorder of glycosylation type 1k (ALG1 gene)	Variant absent
Congenital muscular alpha-dystroglycanopathy and Walker-Warburg syndrome	Variant absent

Sample Report Ultra

Congenital myasthenic syndrome (RAPSN gene)	Variant absent
Congenital stationary night blindness	Variant absent
Cystic fibrosis	Variant absent
Cystinosis	Variant absent
D-Bifunctional Protein Deficiency	Variant absent
Diastrophic dysplasia	Variant absent
Dihydrolipoamide Dehydrogenase Deficiency	Variant absent
Dilated Cardiomyopathy 1D (TNNT2 gene)	Variant absent
Dilated Cardiomyopathy 1DD (RBM20 gene)	Variant absent
Dilated Cardiomyopathy 1E (SCN5A gene)	Variant absent
Dilated Cardiomyopathy 1G (TTN gene)	Variant absent
Dilated Cardiomyopathy 1HH (BAG3 gene)	Variant absent
Dilated Cardiomyopathy 1I (DES gene)	Variant absent
Dilated Cardiomyopathy 1P (PLN gene)	Variant absent
Dilated Cardiomyopathy 1S (MYH7 gene)	Variant absent
Dilated Cardiomyopathy 1Z (TNNC1 gene)	Variant absent
Dilated cardiomyopathy 1A (LMNA gene)	Variant absent
Dubin-Johnson syndrome	Variant absent
Ehlers-Danlos Syndrome (EDS)	Variant absent
Fabry Disease	Variant absent
Familial Arrhythmogenic Right Ventricular Cardiomyopathy	Variant absent
Familial Hypercholesterolemia	Variant absent
Familial Hypertrophic Cardiomyopathy (HCM)	Variant absent
Familial Mediterranean fever	Variant absent
Familial Porphyria Cutanea Tarda (UROD gene)	Variant absent
Familial Thoracic Aortic Aneurysm and Dissection (ACTA2 gene)	Variant absent
Familial Thoracic Aortic Aneurysm and Dissection (MYH11 gene)	Variant absent
Familial adenomatous polyposis	Variant absent
Familial advanced sleep phase syndrome (FASPS)	Variant absent
Familial breast cancer (BRCA1 and BRCA2 genes)	Variant absent
Familial dysautonomia (Riley-Day syndrome)	Variant absent
Familiar hyperinsulinism (ABCC8-related)	Variant absent
Fanconi Anemia (FANCA gene)	Variant absent
Fanconi Anemia (FANCE gene)	Variant absent
Fanconi Anemia (FANCG gene)	Variant absent
Fanconi anemia (FANCC gene)	Variant absent
GCK-related Diabetes (MODY 2)	Variant absent
GRACILE syndrome	Variant absent
Gaucher disease	Variant absent

Sample Report Ultra

Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency)	Variant absent
Glutaric Acidemia type 1	Variant absent
Glutaric Acidemia type 2	Variant absent
Glycogen Storage Disease Type IV	Variant absent
Glycogen Storage Disease Type VI	Variant absent
Glycogen storage disease type 1A (Von Gierke Disease)	Variant absent
Glycogen storage disease type 1B	Variant absent
Glycogen storage disease type 3	Variant absent
Glycogenosis type 5 or McArdle's disease	Variant absent
HNF1A-related Diabetes (MODY 3)	Variant absent
HNF1B-related Diabetes (MODY 5)	Variant absent
HNF4A-related Diabetes (MODY 1)	Variant absent
Hamartoma tumor syndrome (PTEN gene)	Variant absent
Hemophilia A	Variant absent
Hemophilia B	Variant absent
Hereditary Cancer (PALB2 gene)	Variant absent
Hereditary Coproporphyria (CPOX gene)	Variant absent
Hereditary Hemochromatosis Type 2A (HJV gene)	Variant absent
Hereditary Hemochromatosis Type 2B (HAMP gene)	Variant absent
Hereditary Hemochromatosis Type 3 (TFR2 gene)	Variant absent
Hereditary Hemochromatosis Type 4 (SLC40A1 gene)	Variant absent
Hereditary Hemorrhagic Telangiectasia	Variant absent
Hereditary Paraganglioma-Pheochromocytoma Syndrome	Variant absent
Hereditary fructose intolerance	Variant absent
Homocystinuria due to MTHFR deficiency	Variant absent
Hypokalemic Periodic Paralysis	Variant absent
Hypophosphatasia	Variant absent
Junctional Epidermolysis Bullosa	Variant absent
Juvenile Polyposis Syndrome (BMPR1A gene)	Variant absent
Juvenile Polyposis Syndrome (SMAD4 gene)	Variant absent
Leigh Syndrome, French-Canadian type (LSFC)	Variant absent
Leukoencephalopathy with vanishing white matter	Variant absent
Li-Fraumeni Syndrome	Variant absent
Long QT Syndrome Type 3	Variant absent
Long QT Syndrome Types 1 and 2	Variant absent
Long QT Syndrome Types 14, 15, and 16	Variant absent
Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency	Variant absent
Lynch syndrome	Variant absent
Malignant Hyperthermia	Variant absent
Maple syrup urine disease type 1B	Variant absent

Sample Report Ultra

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	Variant absent
Metachromatic leukodystrophy	Variant absent
Methylmalonic Aciduria with Homocystinuria, cblC type	Variant absent
Methylmalonic Aciduria with Homocystinuria, cblD type	Variant absent
Methylmalonic Aciduria with Homocystinuria, cblF type	Variant absent
Methylmalonic Aciduria with Homocystinuria, cblJ type	Variant absent
Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency	Variant absent
Mitochondrial Trifunctional Protein Deficiency	Variant absent
Mucolipidosis II and III alpha/beta	Variant absent
Mucolipidosis III Gamma (GNPTG gene)	Variant absent
Mucolipidosis type IV (MCOLN1 gene)	Variant absent
Multiple Endocrine Neoplasia Type 1	Variant absent
Multiple Endocrine Neoplasia Type 4	Variant absent
Multiple endocrine neoplasia 2B	Variant absent
Neurofibromatosis Type 2	Variant absent
Neurofibromatosis type I	Variant absent
Neuronal Ceroid Lipofuscinosis Type 10 (CTSD gene)	Variant absent
Neuronal Ceroid Lipofuscinosis Type 11 (GRN gene)	Variant absent
Neuronal Ceroid Lipofuscinosis Type 13 (CTSF gene)	Variant absent
Neuronal Ceroid Lipofuscinosis Type 2 (TPP1 gene)	Variant absent
Neuronal Ceroid Lipofuscinosis Type 8 (CLN8 gene)	Variant absent
Neuronal Ceroid-Lipofuscinoses type 1 (associated to PPT1)	Variant absent
Neuronal ceroid lipofuscinosis type 3 (CLN3 gene)	Variant absent
Neuronal ceroid lipofuscinosis type 5 (CLN5 gene)	Variant absent
Neuronal ceroid lipofuscinosis type 6 (CLN6 gene)	Variant absent
Neuronal ceroid lipofuscinosis type 7 (MFSD8 gene)	Variant absent
Niemann-Pick Disease Type C	Variant absent
Niemann-Pick disease type A and B	Variant absent
Non-syndromic mitochondrial hearing loss	Variant absent
Nonsyndromic Hearing Loss and Deafness, DFNB1	Variant absent
Oculocutaneous Albinism (SLC45A2 gene)	Variant absent
Oculocutaneous Albinism (TYRP1 gene)	Variant absent
Oculocutaneous albinism (OCA2 gene)	Variant absent
Oculocutaneous albinism (TYR gene)	Variant absent
Ornithine Transcarbamylase Deficiency	Variant absent
Pendred syndrome	Variant absent
Peters plus syndrome	Variant absent
Peutz-Jeghers Syndrome	Variant absent
Phenylketonuria	Variant absent

Sample Report Ultra

Polymerase Proofreading-Associated Polyposis (POLD1 and POLE genes)	Variant absent
Pontocerebellar Hypoplasia Type 10 (CLP1 gene)	Variant absent
Pontocerebellar Hypoplasia Type 11 (TBC1D23 gene)	Variant absent
Pontocerebellar Hypoplasia Type 1A (VRK1 gene)	Variant absent
Pontocerebellar Hypoplasia Type 1B (EXOSC3 gene)	Variant absent
Pontocerebellar Hypoplasia Type 2B (TSEN2 gene)	Variant absent
Pontocerebellar Hypoplasia Type 2D (SEPSECS gene)	Variant absent
Pontocerebellar Hypoplasia Type 6 (RARS2 gene)	Variant absent
Pontocerebellar Hypoplasia Type 7 (TOE1 gene)	Variant absent
Pontocerebellar Hypoplasia Type 8 (CHMP1A gene)	Variant absent
Pontocerebellar Hypoplasia Type 9 (AMPD2 gene)	Variant absent
Pontocerebellar hypoplasia types 2A, 4, and 5 (TSEN54 gene)	Variant absent
Primary Hyperoxaluria Type 3 (PH3)	Variant absent
Primary Pyruvate Dehydrogenase Complex Deficiency	Variant absent
Primary hyperoxaluria type 1 (PH1)	Variant absent
Primary hyperoxaluria type 2 (PH2)	Variant absent
Pyridoxine-dependent epilepsy	Variant absent
Pyruvate kinase deficiency	Variant absent
Recessive Retinopathy (RPE65 gene)	Variant absent
Refsum disease	Variant absent
Retinitis Pigmentosa with or without Skeletal Abnormalities	Variant absent
Retinoblastoma	Variant absent
Rhizomelic Chondrodyplasia Punctata Type 1	Variant absent
Rhizomelic Chondrodyplasia Punctata Type 2	Variant absent
Rhizomelic Chondrodyplasia Punctata Type 3	Variant absent
Salla Disease	Variant absent
Short chain acyl-CoA dehydrogenase deficiency (SCADD)	Variant absent
Sjögren-Larsson syndrome	Variant absent
Spastic Paraplegia (ATL1 gene)	Variant absent
Spastic Paraplegia (SPAST gene)	Variant absent
Spastic Paraplegia with Pelizaeus-Merzbacher Disease (PLP1 gene)	Variant absent
Systemic Amyloidosis (FGA gene)	Variant absent
Tay-Sachs disease	Variant absent
Transthyretin amyloidosis (TTR gene)	Variant absent
Tuberous Sclerosis	Variant absent
Tyrosinemia Type II	Variant absent
Tyrosinemia type I	Variant absent
Usher syndrome	Variant absent
Variegate Porphyria (PPOX gene)	Variant absent

Sample Report Ultra

Very long chain acyl-CoA dehydrogenase deficiency (VLCADD)	Variant absent
Visceral Amyloidosis (APOA1 gene)	Variant absent
Von Hippel-Lindau Syndrome	Variant absent
Wilms Tumor 1 (WT1 gene)	Variant absent
Wilson disease	Variant absent
X-linked Adrenoleukodystrophy	Variant absent
X-linked Congenital Stationary Night Blindness	Variant absent
X-linked Dominant Rhizomelic Chondrodysplasia Punctata	Variant absent
X-linked Recessive Rhizomelic Chondrodysplasia Punctata	Variant absent
X-linked Retinitis Pigmentosa	Variant absent
Zellweger syndrome	Variant absent
cb1A Type Methylmalonic aciduria	Variant absent
cb1B Type Methylmalonic aciduria	Variant absent
von Willebrand disease	Variant absent

Sample Report Ultra

Name: DEMO ULTRA

Date: 01-23-2026

Ancestry

Europe	100%
Iberian Peninsula	62.8%
Spain	Detected
Portugal	Detected
Basques	Detected
Italy	24.1%
Northern Italy	Detected
Central-Southern Italy and Sicily	Detected
British Isles and Ireland	6.9%
United Kingdom	Detected
Ireland	Detected
Sardinia	6.2%

Paternal Lineage

Paternal Haplogroup	R1b
---------------------	-----

Maternal Lineage

Maternal Haplogroup	v
---------------------	---

Neanderthal

DNA Neanderthal	2.6%
-----------------	------

Sample Report Ultra

Name: DEMO ULTRA

Date: 01-23-2026

Name	Results
Antioxidant capacity	Slightly lower than average capacity
Apolipoprotein A1 levels	Low levels
Apolipoprotein B levels	Low levels
Bitter taste perception	Ability to perceive bitter taste
Blood glucose	Low levels
Body fat percentage	Low percentage
Body mass index	High body mass index
Bone mineral density	Low density
Caffeine and anxiety	Average levels of caffeine cravings
Caffeine and sports performance	Increased performance
Caffeine dependence after prolonged consumption	Low caffeine dependence
Calcium levels	Low levels
Celiac disease predisposition	Absence of predisposition
Creatinine levels	High levels
Diastolic blood pressure levels	Low levels
Exercise-induced muscle damage (initial phase)	Medium risk
Exercise-induced muscle damage (regeneration capacity)	Slower regeneration
Exercise-induced muscle damage (second phase)	Medium risk
Farmer-hunter profile	Farmer profile
Food intake control	Slight tendency to overeat
Galectin-3 levels	Low levels
Genetic predisposition to peanut allergy	Slight predisposition to increase
Glycated hemoglobin levels	High levels
HDL cholesterol levels	High levels
Histamine intolerance	Probability of mild DAO deficiency and histamine intolerance.
Intraocular pressure	Average levels
Lactose intolerance	High probability of being intolerant
LDL cholesterol levels	Low levels
Levels of vitamin A (beta carotene)	Slightly high levels
Long-chain omega fatty acids levels	Average levels
Lung function (exhaled air volume)	Average volume

Muscle endurance	Increased probability of being a sprinter
Myoadenylate deaminase (AMPD1 gene)	You do not have the C34T variant in the AMPD1 gene.
Prediction of visceral adipose tissue	Average adipose tissue volume
Preference for sweets	Average probability
Serum phosphate levels	Low levels
Systolic blood pressure levels	Average levels
Tendinopathies in lower extremities (legs)	Low risk
Tendinopathies in upper extremities (arms)	High risk
Urate levels	High levels
Vitamin B12 levels	Average levels
Vitamin C levels	Low levels
Vitamin D levels	Low levels
Vitamin E levels	Slightly low levels

Sample Report Ultra

Name: DEMO ULTRA

Date: 01-23-2026

Name	Results
Acne vulgaris	High probability of having acne
Alanine aminotransferase levels	Low levels
Alcohol dependence after prolonged consumption	Low alcohol dependence
Alcohol flush reaction	Low probability of presenting the reaction
Alkaline phosphatase levels	High levels
Asparagus odor detection	Reduced ability to detect asparagus odor in urine
Aspartate aminotransferase levels	Low levels
Basal metabolic rate	Low basal metabolic rate
Bilirubin levels	Average levels
Birth weight	Low birth weight
Blood coagulation, factor V Leiden and 20210G-A	Absence of both mutations
Blood Group ABO/Rh	Inconclusive result
C-reactive protein levels	Low levels
Cathepsin D levels	Low levels
Cognitive ability	High cognitive ability
Corneal curvature	Average curvature
Corneal hysteresis	Low hysteresis
Dental caries and periodontitis	Average probability
Duffy Antigen, malaria resistant	Lower resistance
Earlobe type	Low probability of having an attached lobe
Eosinophil count	Low count
Epigenetic aging	Increased epigenetic age
Estradiol levels	Low levels
Eye clarity	Dark eyes (dark brown and black)
Facial aging	Increased probability
Frequency of bowel movements	High frequency
Gamma glutamyl transferase levels	High levels
Gene COMT	You do not have the V158M variant in the COMT gene
Gene MTHFR	You do not have the A1298C and C677T variants in the MTHFR gene.
Gene MTR	You do not have the A2756G variant in the MTR gene

Gene MTRR	You have one copy of the A66G variant in the MTRR gene
Hair color	Light hair (blond and light brown)
Hair Shape	High probability of having straight hair
Heat production in response to cold	Stimulation of normal thermogenesis in response to cold.
Height	Tall height
HLA-B27 antigen	Absence of the feature
Insomnia	Average probability of suffering from insomnia
Intensity of itching due to mosquito bites	High itching intensity
Left-handedness (left lateral)	Lower probability of being left-handed
Liver iron levels	High levels
Lymphocyte count	High count
Male baldness	High probability of baldness
Mental agility	Average mental agility
Monocyte count	Low count
Morning circadian rythm (Morning person)	High probability of a morning circadian rhythm
Mouth ulcers	High probability
Neuroticisms	Increased probability
Neutrophil count	Low count
Nicotine dependence after prolonged consumption	Medium nicotine dependence
Permanent tooth eruption	Susceptibility in the mean
Persistence of fetal hemoglobin	Lower persistence
Photic sneeze reflex	Absence of the feature
Pigmented rings on the iris	More pronounced pigmentation rings
Probability of having red hair	Low probability of being a redhead
Probability of snoring	Increased probability
PSA (Prostate Specific Antigen) Levels	Slightly low levels
QT Intervals	Short interval
Red blood cell count	Low count
Resistin levels	High levels
Resting heart rate	Low heart rate
Risk tendency	High probability of being a risk-taker
Secretor status and ABH antigens (FUT2 gene)	Non-secretory state (Caucasians)
Selectin E levels	Low levels
Serum albumin levels	Average levels
Sex hormone regulation (SHBG)	Low levels
Skin melanin levels	High skin melanin levels
Sleep duration	Average sleep duration
Smell	Ability to perceive the floral aroma
Spleen volume	Medium Volume

Telomere length	Average length
Thyroid function (TSH levels)	Low levels
Tooth morphology	Incisors without shovel shape
Total serum protein levels	Low levels
Usual walking pace	Low rhythm
White blood cell count	Low count

Sample Report Ultra

Name: DEMO ULTRA

Date: 01-23-2026

Name	Pharmacological action	Results
Brivaracetam (Dosage)	Antiepileptics	Consider reducing the dose
Carbamazepine (Dosage)	Antiepileptics	A higher dose of carbamazepine would be necessary.
Citalopram (Dosage)	Antidepressants	Consider lower maintenance doses
Clobazam (Adverse Reactions)	Muscle relaxants	Higher probability of adverse effects
Clopidogrel (Dosage)	Antithrombotics	Evaluate dose or alternative drug according to specific vascular condition
Docetaxel (Adverse effects)	Antineoplastics	Increased risk of adverse effects, leukopenia and neutropenia (Asians)
Escitalopram (Dosage)	Antidepressants	Consider lower maintenance doses
Ivacaftor (Efficacy)	Other drugs for the respiratory system	In the case of cystic fibrosis, the use of ivacaftor is not recommended
Olanzapine (Efficacy)	Antipsychotics	Probable worse response to treatment
Peginterferons alfa-2a -2b and ribavirin (Efficacy)	Antivirals	Lower probability of response
Abacavir (Adverse effects)	Antivirals	Lower risk of hypersensitivity
Acenocoumarol, Fenprocoumon (Adverse effects)	Antithrombotics	Risk of adverse effects without variations
Allopurinol (Dosage)	Antigout	Treatment with standard doses is recommended
Amifampridine (Dosage)	Cholinergics	Probably rapid NAT2 acetylator. Usual dose
Amitriptyline (Dosage)	Antidepressants	Start treatment with the standard dose
Aripiprazole (Dosage)	Antipsychotics	Employ the recommended dose
Atazanavir (Adverse effects)	Antivirals	Very low probability of hyperbilirubinemia
Atomoxetine (Dosage)	Centrally acting psychostimulants	Use the recommended dose
Atorvastatin (Dosage)	Hypolipidemic agents	Use the recommended dose
Brexpiprazole (Dosage)	Antipsychotics	Use the recommended dose
Celecoxib (Dosage)	Non-steroidal anti-inflammatory drugs	Initiate treatment with the recommended dose
Cisplatin (Adverse Reactions)	Antineoplastics	Typical risk of ototoxicity
Clomipramine (Dosage)	Antidepressants	Start treatment with the standard dose
Codeine (Dosage)	Opioid analgesics	Use the recommended dose
Daunorubicin, Doxorubicin (Adverse Reactions)	Antineoplastics	Moderate risk of cardiotoxicity
Desipramine (Dosage)	Antidepressants	Use the recommended dose
Diazepam (Adverse Reactions)	Anxiolytics	Typical probability of adverse effects

Doxepin (Dosage)	Antidepressants	Initiate treatment with the standard dose
Efavirenz (Adverse effects)	Antivirals	Low risk of adverse reactions
Eliglustat (Adverse Reactions)	Treatment of metabolic diseases	Typical risk of adverse effects
Fentanyl (Efficacy)	Opioid analgesics	No variation in response
Flecainide (Dosage)	Antiarrhythmics	Use the recommended dose
Floxacillin (Adverse effects)	Antibiotics	Risk of adverse effects without variations
Flucytosine (Adverse Reactions)	Antifungals	Normal risk of toxicity
Fluindione (Adverse Reactions)	Antithrombotics	Lower probability of bleeding at standard doses
Fluorouracil, Capecitabine (Dosage)	Antineoplastics	Use the recommended dose
Flurbiprofen (Dosage)	Anti-inflammatory	Initiate treatment with the recommended dose
Fluvastatin (Dosage)	Hypolipidemic agents	Initiate treatment with the recommended dose
Fluvoxamine (Dosage)	Antidepressants	Start treatment with standard dose
G6PD Deficiency and Adverse Drug Reactions	Multiple pharmacological actions	Risk of adverse effects without variations
Haloperidol (Dosage)	Antipsychotics	Start treatment with standard dose
Hydrochlorothiazide (Efficacy)	Antihypertensives	No variation in response
Hydrocodone (Dosage)	Opioid analgesics	Start treatment with standard dose
Ibuprofen (Dosage)	Anti-inflammatory	Start the treatment with the recommended dose
Iloperidone (Dosage)	Antipsychotics	Employ the recommended dose
Imipramine (Dosage)	Antidepressants	Start treatment with the standard dose
Inhalation anesthetics and succinylcholine (Adverse Reactions)	General anesthetics	Low risk of developing malignant hyperthermia (see report)
Irinotecan (Adverse effects)	Antineoplastics	Start treatment with standard dose
Isoniazid (Adverse effects)	Antibiotics	Probably rapid NAT2 acetylator. Lower risk of liver toxicity
Lansoprazole, Dexlansoprazole (Dosage)	Anti-acid treatment	Start treatment with standard dose
Lornoxicam (Dosage)	Anti-inflammatory	Initiate treatment with the recommended dose
Lovastatin (Dosage)	Hypolipidemic agents	Start treatment with standard dose
Lumacaftor + Ivacaftor (Efficacy)	Other drugs for the respiratory system	Cystic Fibrosis treatment with lumacaftor/ivacaftor not recommended
Meloxicam (Dosage)	Anti-inflammatory	Start treatment with standard dose
Methotrexate (Adverse Reactions)	Immunomodulators	Reduced risk of toxicity
Methotrexate in rheumatoid arthritis (Efficacy)	Immunomodulators	Effective response to treatment
Metoprolol (Dosage)	Beta-blockers cardiovascular system	Start treatment with standard dose
Mivacurium and succinylcholine (Adverse Reactions)	Muscle relaxants	Low risk of prolonged neuromuscular blockade
Nilotinib (Adverse Reactions)	Antineoplastics	Lower risk of adverse reactions
Nortriptyline (Dosage)	Antidepressants	Start treatment with the recommended dose
Olanzapine (Adverse effects)	Antipsychotics	Reduced likelihood of certain adverse effects
Omeprazole (Dosage)	Anti-acid treatment	Start treatment with standard dose

Pantoprazole (Dosage)	Anti-acid treatment	Start treatment with standard dose
Paroxetin (Dosage)	Antidepressants	Start treatment with standard dose
Phenytoin (Dosage)	Antiepileptics	Employ the recommended dose
Pimozide (Dosage)	Antipsychotics	Initiate treatment with the recommended dose
Piroxicam (Dosage)	Anti-inflammatory	Start treatment with standard dose
Pitavastatin (Dosage)	Hypolipidemic agents	Start treatment with standard dose
Pitolisant (Dosage)	Other nervous system drugs	Start therapy with standard dose
Pravastatin (Dosage)	Hypolipidemic agents	Start treatment with standard dose
Propafenone (Adverse Reactions)	Antiarrhythmics	Start treatment with standard dose
Risperidone (Dosage)	Antipsychotics	Start treatment with standard dose
Rosuvastatin (Dosage)	Hypolipidemic agents	Initiate treatment with the standard dose
Selective Serotonin Reuptake Inhibitors (SSRIs) (Adverse effects)	Antidepressants	No variations in the likelihood of sexual dysfunction associated with SSRI treatment
Sertraline (Dosage)	Antidepressants	Initiate treatment with the standard dose and monitor
Simvastatin (Dosage)	Hypolipidemic agents	Start treatment with standard dose
Siponimod (Dosage)	Immunosuppressants	Start treatment with standard dose
Tacrolimus (Dosage)	Immunosuppressants	Start treatment with standard dose
Tamoxifen (Efficacy)	Antineoplastics	Initiate treatment with standard dose
Tenoxicam (Dosage)	Anti-inflammatory	Start treatment with the recommended dose
Thioguanine, Azathioprine, Mercaptopurine (Dosage)	Immunosuppressants	Start treatment with standard dose
Tramadol (Dosage)	Opioid analgesics	Use standard doses
Trimipramine (Dosage)	Antidepressants	Initiate treatment with the standard dose
Valproic Acid (Adverse effects)	Antiepileptics	No variations in liver toxicity risk
Venlafaxine (Dosage)	Antidepressants	Start treatment with standard dose
Voriconazole (Dosage)	Antifungals	Start treatment with standard dose
Vortioxetine (Dosage)	Antidepressants	Start treatment with standard dose
Warfarin (Adverse Reactions)	Antithrombotics	Risk of adverse effects without variations
Zuclopentixol (Dosage)	Antipsychotics	Start treatment with standard dose

Name: DEMO ULTRA

Date: 01-23-2026

Name	Results
Abdominal aortic aneurysm	Slightly low risk
Abdominal hernia	Slightly high risk
Actinic keratosis	Medium risk
Addison's disease	Medium risk
Adolescent idiopathic scoliosis	High risk
Age-related hearing impairment	Medium risk
Age-related macular degeneration	Medium risk
Allergic rhinitis	Medium risk
Alzheimer's disease	Medium risk
Amyotrophic lateral sclerosis	Medium risk
Angina pectoris	Medium risk
Anxiety	Medium risk
Arterial hypertension	Medium risk
Asthma	Medium risk
Atopic dermatitis	Medium risk
Atrial fibrillation	Low risk
Barrett's esophagus	Slightly high risk
Basal cell carcinoma	Medium risk
Benign prostatic hyperplasia	Medium risk
Bipolar disorder	Medium risk
Carpal tunnel syndrome	Medium risk
Cataracts	Slightly high risk
Chronic kidney disease	Medium risk
Chronic lymphocytic leukemia	Medium risk
Chronic Obstructive Pulmonary Disease	Slightly low risk
Colon polyp	Medium risk
Colorectal cancer	Medium risk
Coronary heart disease	Medium risk
Crohn's disease	Medium risk
Cutaneous malignant melanoma	Medium risk
Deep vein thrombosis	Slightly low risk
Depression	Medium risk

Sample Report Ultra

Diabetes mellitus type 1	Medium risk
Diabetes mellitus type 2	Slightly high risk
Diaphragmatic hernia	Medium risk
Diverticulosis - Diverticulitis	Medium risk
Dupuytren's disease	Slightly low risk
Fasciitis	Medium risk
Gallstones	Slightly low risk
Gastroesophageal reflux disease	Slightly low risk
General osteoarthritis	Slightly low risk
Glioblastoma	Slightly low risk
Glioma	Low risk
Gout	Medium risk
Graves' disease	Slightly low risk
Haemorrhoidal disease	Medium risk
Hallux valgus	Slightly low risk
Hashimoto's thyroiditis	Medium risk
Headaches	Medium risk
Heart failure	Medium risk
Hypercholesterolemia	Medium risk
Hyperlipidemia	Medium risk
Hypothyroidism	Medium risk
Idiopathic pulmonary fibrosis	Slightly low risk
Inguinal hernia	Medium risk
Intracranial aneurysm	Medium risk
Ischemic stroke	Medium risk
Juvenile idiopathic arthritis	Medium risk
Keratoconus	Medium risk
Lung cancer	Medium risk
Macular telangiectasia type 2	Medium risk
Migraines	Medium risk
Monoclonal Gammopathy of Uncertain Significance	Slightly low risk
Multiple myeloma	Medium risk
Multiple sclerosis	Low risk
Myeloproliferative neoplasms	Medium risk
Myocardial infarction	Low risk
Narcolepsy	Slightly low risk
Nasal polyps	Medium risk
Neuroblastoma	Medium risk
Non-alcoholic fatty liver disease	Medium risk

Sample Report Ultra

Non-celiac intestinal malabsorption	Slightly low risk
Non-medullary thyroid cancer	Low risk
Non-syndromic cleft lip	Medium risk
Non-toxic multinodular goiter	Medium risk
Open angle glaucoma	Medium risk
Oral cavity and oropharyngeal cancer	Medium risk
Osteoarthritis of the hip	Slightly low risk
Osteoarthritis of the knee	Slightly low risk
Osteoporosis	Slightly high risk
Pancreatic cancer	Medium risk
Parkinson's disease	Slightly low risk
Peripheral arterial disease	Slightly low risk
Primary Biliary Cirrhosis	Medium risk
Prostate cancer	Medium risk
Psoriasis	Slightly high risk
Pulmonary embolism	Low risk
Restless legs syndrome	Slightly high risk
Rheumatoid arthritis	Slightly low risk
Sarcoidosis	Medium risk
Schizophrenia	Medium risk
Sensorineural hearing loss	Medium risk
Spinal canal stenosis	Slightly high risk
Squamous cell carcinoma of the skin	Medium risk
Systemic lupus erythematosus	Slightly high risk
Systemic sclerosis	Medium risk
Testicular germ cell cancer	Slightly high risk
Ulcerative colitis	Medium risk
Urolithiasis	Medium risk
Varicose veins	High risk
Vitiligo	Slightly high risk

Sample Report Ultra